Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KRISTI K GEORGE

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1770587479
CMS profile
352626
Location
INDIANAPOLIS, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,106.55

217 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KRISTI K GEORGE

NPI 1770587479 · CMS profile ID 352626

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

INDIANAPOLIS, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1770587479?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KRISTI K GEORGE, NPI 1770587479, CMS profile ID 352626. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1770587479?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). KRISTI K GEORGE, NPI 1770587479, CMS profile ID 352626. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1770587479?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
KRISTI K GEORGE, NPI 1770587479, CMS profile ID 352626, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1770587479?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

217 matching records · $3,106.55 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 217 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 217.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $16.8607/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662611833 CMS
Genentech USA, Inc. $11.3607/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681358055 CMS
Akcea Therapeutics, Inc. $150.4307/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703185665 CMS
Biogen, Inc. $13.1907/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660635483 CMS
Lilly USA, LLC $0.7506/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657960037 CMS
Lilly USA, LLC $4.8006/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657963511 CMS
Lilly USA, LLC $0.4406/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657973845 CMS
Lilly USA, LLC $5.0906/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657973847 CMS
Supernus Pharmaceuticals, Inc. $1.5806/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702305963 CMS
Sunovion Pharmaceuticals Inc. $11.1306/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687991075 CMS
Neurocrine Biosciences, Inc. $18.8806/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693128807 CMS
PORTOLA PHARMACEUTICALS, INC. $25.2806/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705265405 CMS
Avanir Pharmaceuticals, Inc. $18.1406/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653594973 CMS
Supernus Pharmaceuticals, Inc. $6.6806/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702305961 CMS
ACADIA Pharmaceuticals Inc $15.3006/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700002739 CMS
GENZYME CORPORATION $9.8906/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694122663 CMS
Supernus Pharmaceuticals, Inc. $0.9706/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702305959 CMS
GENZYME CORPORATION $18.3906/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694081169 CMS
Novartis Pharmaceuticals Corporation $22.0006/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659641977 CMS
Adamas Pharmaceuticals, Inc. $11.2006/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694965745 CMS
Sunovion Pharmaceuticals Inc. $5.1606/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687991073 CMS
CSL Behring $17.8606/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683869077 CMS
Novartis Pharmaceuticals Corporation $19.8306/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659641941 CMS
Supernus Pharmaceuticals, Inc. $7.4106/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702305957 CMS
ACADIA Pharmaceuticals Inc $13.2006/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700002737 CMS
EISAI INC. $16.0105/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697008395 CMS
Saol Therapeutics Inc. $15.8005/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698888295 CMS
Allergan Inc. $21.9305/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670402317 CMS
Scilex Pharmaceuticals Inc. $15.8305/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 689473969 CMS
Neurocrine Biosciences, Inc. $15.3405/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693128805 CMS
EMD Serono, Inc. $12.2205/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703002867 CMS
Supernus Pharmaceuticals, Inc. $0.3805/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702305955 CMS
Genentech USA, Inc. $12.1705/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681266213 CMS
Alexion Pharmaceuticals, Inc. $16.9405/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695551249 CMS
Greenwich Biosciences, Inc. $13.1605/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701798661 CMS
Amgen Inc. $15.4805/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662611831 CMS
Supernus Pharmaceuticals, Inc. $7.4105/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702305953 CMS
Supernus Pharmaceuticals, Inc. $0.4105/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702305951 CMS
PFIZER INC. $13.0905/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672040601 CMS
Allergan Inc. $12.6505/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670402311 CMS
LivaNova USA, Inc. $14.9805/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703465425 CMS
Supernus Pharmaceuticals, Inc. $0.9105/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702305949 CMS
ACADIA Pharmaceuticals Inc $13.6705/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700002735 CMS
Supernus Pharmaceuticals, Inc. $6.7205/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702305947 CMS
Avanir Pharmaceuticals, Inc. $14.3904/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653594979 CMS
Sunovion Pharmaceuticals Inc. $12.4604/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687991071 CMS
CSL Behring $15.6604/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683869119 CMS
Supernus Pharmaceuticals, Inc. $1.2004/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702305945 CMS
Neurocrine Biosciences, Inc. $19.6304/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693128803 CMS
Allergan Inc. $19.3304/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670402309 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,106.55 217
PY2020 $1,626.57 127
PY2021 $2,216.73 134
PY2022 $2,657.77 162
PY2023 $3,355.46 178
PY2024 $4,643.33 215
PY2025 $3,996.65 189

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,168,816.07 32
PY2024 Principal investigator $880,640.08 56
PY2023 Recipient $3,494.46 4
PY2023 Principal investigator $1,224,298.31 63
PY2022 Recipient $17,753.70 7
PY2022 Principal investigator $1,926,237.09 44
PY2021 Recipient $10,274.50 1
PY2021 Principal investigator $1,581,920.72 53
PY2020 Recipient $132,542.32 31
PY2020 Principal investigator $755,554.99 20
PY2019 Recipient $119,964.05 11
PY2019 Principal investigator $1,286,491.14 25

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

32 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $150.00 12/31/2025 Non-covered Recipient Entity
JWM NEUROLOGY
A Phase 3, Multicenter, Open-Label 156-Week Extension Study To Evaluate The Long-Term Safety And Tolerability Of Oral Atogepant For The Prevention Of Migraine In Participants With Chronic Or Episodic Migraine No dispute reported 06/30/2026 1202532689
Principal investigator 1 ABBVIE INC. $77.25 12/31/2025 Non-covered Recipient Entity
JWM NEUROLOGY
A Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-552 in Participants with Mild Alzheimer's Disease No dispute reported 06/30/2026 1202532691
Principal investigator 1 Novo Nordisk AS $649.80 12/22/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY, PC
NN6535-4725 No dispute reported 06/30/2026 1213774237
Principal investigator 1 Novo Nordisk AS $2,910.60 09/19/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY, PC
NN6535-4725 No dispute reported 06/30/2026 1213791861
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,500.00 09/18/2025 Non-covered Recipient Entity
Josephson Wallack Munshower Neurology, PC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 2) No dispute reported 06/30/2026 1235996413
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,150.25 08/26/2025 Non-covered Recipient Entity
Josephson Wallack Munshower Neurology, PC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 2) No dispute reported 06/30/2026 1235996415
Principal investigator 1 Novo Nordisk AS $3,200.85 07/16/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY, PC
NN6535-4725 No dispute reported 06/30/2026 1213709042
Principal investigator 1 Novo Nordisk AS $649.80 06/23/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY, PC
NN6535-4725 No dispute reported 06/30/2026 1213779947
Principal investigator 1 ABBVIE INC. $1,000.00 06/10/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUR
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine No dispute reported 06/30/2026 1202490771
Principal investigator 1 ABBVIE INC. $75.00 04/25/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUR
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine No dispute reported 06/30/2026 1202479501
Principal investigator 1 Novo Nordisk AS $586.00 04/21/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY, PC
NN6535-4725 No dispute reported 06/30/2026 1213746113
Principal investigator 1 Novo Nordisk AS $1,743.30 04/21/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY, PC
NN6535-4725 No dispute reported 06/30/2026 1213830088
Principal investigator 1 Novo Nordisk AS $649.80 03/28/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY, PC
NN6535-4725 No dispute reported 06/30/2026 1213707177
Principal investigator 1 ABBVIE INC. $1,060.00 03/20/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUR
M23-515 - Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1202464958
Principal investigator 1 Eli Lilly and Company $128,380.00 02/24/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187885174
Principal investigator 1 Novo Nordisk AS $817.65 02/21/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY, PC
NN6535-4725 No dispute reported 06/30/2026 1213724216
Principal investigator 1 ABBVIE INC. $799.50 02/19/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
M21-307 - Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202452506
Principal investigator 1 ABBVIE INC. $1,050.00 02/11/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUR
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine No dispute reported 06/30/2026 1202450523
Principal investigator 1 Eli Lilly and Company $204,432.00 02/11/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187885794
Principal investigator 1 Eli Lilly and Company $3,542.32 02/10/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187883174
Principal investigator 1 ABBVIE INC. $1,500.00 02/04/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
M21-307 - Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202443756
Principal investigator 1 Eli Lilly and Company $3,542.18 01/31/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187886684
Principal investigator 1 Novo Nordisk AS $5,809.05 01/31/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY, PC
NN6535-4725 No dispute reported 06/30/2026 1213715582
Principal investigator 1 Eli Lilly and Company $766.50 01/27/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY
LONG-TERM REAL-WORLD COMPARATIVE EFFECTIVENESS OF DONANEMAB PLUS USUAL CARE VERSUS USUAL CARE ALONE IN US PATIENTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE (TRAILBLAZER-REAL US) No dispute reported 06/30/2026 1187883172
Principal investigator 1 Eli Lilly and Company $4,369.53 01/27/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187884146
Principal investigator 1 Eli Lilly and Company $134,488.10 01/22/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187886682
Principal investigator 1 Eli Lilly and Company $9,180.00 01/21/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187886678
Principal investigator 1 UCB SA $28,275.00 01/17/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY P.C
A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED Parkinsons DISEASE No dispute reported 06/30/2026 1246658462
Principal investigator 1 Eli Lilly and Company $5.79 01/09/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187883022
Principal investigator 1 Eli Lilly and Company $2,619,623.00 01/06/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY
LONG-TERM REAL-WORLD COMPARATIVE EFFECTIVENESS OF DONANEMAB PLUS USUAL CARE VERSUS USUAL CARE ALONE IN US PATIENTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE (TRAILBLAZER-REAL US) No dispute reported 06/30/2026 1187886680
Principal investigator 1 ABBVIE INC. $322.80 01/03/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUR
M23-515 - Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1202436411
Principal investigator 1 ABBVIE INC. $1,510.00 01/02/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUR
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine No dispute reported 06/30/2026 1202434387